Publication:
Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.

dc.contributor.authorKluge, Regine
dc.contributor.authorWittig, Tim
dc.contributor.authorGeorgi, Thomas W
dc.contributor.authorKurch, Lars
dc.contributor.authorSabri, Osama
dc.contributor.authorWallace, W Hamish
dc.contributor.authorKlekawka, Tomasz
dc.contributor.authorFernández-Teijeiro, Ana
dc.contributor.authorCeppi, Francesco
dc.contributor.authorKarlén, Jonas
dc.contributor.authorPears, Jane
dc.contributor.authorCepelová, Michaela
dc.contributor.authorFosså, Alexander
dc.contributor.authorBeishuizen, Auke
dc.contributor.authorHjalgrim, Lisa Lyngsie
dc.contributor.authorKörholz, Dieter
dc.contributor.authorMauz-Körholz, Christine
dc.contributor.authorHasenclever, Dirk
dc.date.accessioned2023-02-09T09:38:08Z
dc.date.available2023-02-09T09:38:08Z
dc.date.issued2020-08-06
dc.description.abstractIn first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1-3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments. Results: Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable. Conclusion: The findings support that first- and second-line treatments in HL do not require different response criteria.
dc.identifier.doi10.2967/jnumed.120.247924
dc.identifier.essn1535-5667
dc.identifier.pmid32764122
dc.identifier.unpaywallURLhttps://jnm.snmjournals.org/content/jnumed/62/3/338.full.pdf
dc.identifier.urihttp://hdl.handle.net/10668/16064
dc.issue.number3
dc.journal.titleJournal of nuclear medicine : official publication, Society of Nuclear Medicine
dc.journal.titleabbreviationJ Nucl Med
dc.language.isoen
dc.organizationHospital Universitario Virgen Macarena
dc.page.number338-341
dc.pubmedtypeComparative Study
dc.pubmedtypeJournal Article
dc.rights.accessRightsopen access
dc.subjectHodgkin lymphoma
dc.subjectPET response criteria
dc.subjectrelapse
dc.subject.meshAdolescent
dc.subject.meshChild
dc.subject.meshDisease Progression
dc.subject.meshFemale
dc.subject.meshHodgkin Disease
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshPositron-Emission Tomography
dc.subject.meshRecurrence
dc.subject.meshTreatment Outcome
dc.titleComparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number62
dspace.entity.typePublication

Files